[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-384212-105":59,"doc-detail-384212-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","novel-therapeutic-options-for-small-cell-lung-cancer","Novel Therapeutic Options for Small Cell Lung Cancer","","This review focuses on recent advances in the molecular knowledge of small cell lung cancer (SCLC) and on promising emerging treatments, including approaches targeting the DNA damage pathway, epigenetic mechanisms, angiogenesis, and oncogenic drivers. It highlights how the addition of immunotherapy to chemotherapy has improved clinical outcomes in this aggressive neoplasia, while prognosis remains poor. Progress in genomic alteration discovery supports molecular subdivision and future target development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/novel-therapeutic-options-for-small-cell-lung-cancer/384212/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/novel-therapeutic-options-for-small-cell-lung-cancer/384212.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the review on small cell lung cancer?","Question",{"text":112,"@type":113},"To summarize recent advances in the molecular understanding of SCLC and potential new treatment strategies, including pathway, epigenetic, angiogenesis, and oncogenic-driver targeting.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How has immunotherapy changed outcomes in extensive-disease SCLC?",{"text":117,"@type":113},"Adding immunotherapy to chemotherapy has significantly improved clinical outcomes and overall survival, even though the prognosis remains dismal.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is molecular classification important for SCLC treatment development?",{"text":121,"@type":113},"Multiple genomic alterations enable stratification into molecular subtypes, which may help identify therapeutic targets and guide more effective targeted treatment strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},384212,1791306820,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Novel Therapeutic Options for Small Cell Lung Cancer  \nStefania Canova1 · Benedetta Trevisan1,2 · Maria Ida Abbate1 · Francesca Colonese1 · Luca Sala1 · Alice Baggi1,2 · Sofia Paola Bianchi3,4 · Anna D’Agostino1 · Diego Luigi Cortinovis1,5  \nAccepted: 19 September 2023 / Published online: 23 October 2023 © The Author(s) 2023  \nAbstract  \nPurpose of Review The aim of this review is to focus on the recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential promising new treatment strategies, like targeting the DNA damage pathway, epigenetics, angiogenesis, and oncogenic drivers.  \nRecent Findings In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Recently, numerous genomic alterations have been identified, and they may be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, SCLC-Y, SCLC-P) .  \nSummary SCLC accounts for 10-20% of all lung cancers, most patients have an extensive disease at the diagnosis, and it is characterized by poor prognosis. Despite the progresses in the knowledge of the disease, efficacious targeted treatments are still lacking. In the near future, the molecular characterisation of SCLC will be fundamental to find more effective treatment strategies.  \nKeywords SCLC classification · Target therapy · Immunotherapy · PARP inhibitors  \nIntroduction  \nSmall cell lung cancer (SCLC) accounts for about 10–20% of all lung cancers and it is characterized by a high rate of proliferation, early metastases, and poor prognosis [1 , 2] . As many as 98% of patients are smokers providing direct evidence that tobacco carcinogens are responsible for the initiation of SCLC [2 , 3] . About 70% of patients  \nStefania Canova and Benedetta Trevisan contributed to the paper.  \n* Diego Luigi Cortinovis [diegoluigi.cortinovis@irccs-sangerardo.it](diegoluigi.cortinovis@irccs-sangerardo.it)  \n1 SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy  \n2 Department of Medical-Surgical Specialties, University of Brescia, Radiological Sciences and Public Health, Brescia, Italy  \n3 Radiation Oncology Department, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy  \n4 School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy  \n5 Medicine and Surgery Department, University of Milano Bicocca, Milan, Italy  \nhave extensive disease (ED-) at diagnosis with a 2-year survival rate of approximately 2%[4] . For more than 30 years, chemotherapy (CT) with platinum and etoposide (PE) has been the standard front-line therapy [5, 6] . The introduction of immune checkpoint inhibitors (ICIs) set a new step in clinical practice for patients with ED-SCLC [7••] .  \nAs demonstrated by IMpower133 and CASPIAN, beyond others first-line trials conducted in asiatic population such as CAPSTONE-1 and ASTRUM-005, the addition of ICI to first-line platinum-based chemotherapy significantly improved overall survival (OS) with a reduction of 25 to 30% of the relative risk of death [7••, 8, 9••, 10]. Nevertheless, more research is needed to further improve this dismal benefit. Although SCLC is characterized by numerous genomic alterations, effective targeted therapies are still lacking. Indeed, over the past decade, the complete genomic profile of SCLC has highlighted a broad and complex genetic landscape of this tumour, including somatic mutations on transcription factors, receptor tyrosine kinases genes, and epigenetic changes in chromatin modifiers enzymes [2, 11–14] . However, all the trials to date have failed to demonstrate a survival benefit from using targeted agents. A deeper study of molecular aberrations could lead to the identification of new therapeutic targets [9••, 15] .  \nToward a New Molecular Classification  \nDespite almost all cases of SCLC have total genomic loss of function of both TP53 and RB1, and are treated as a ","cbCaigEt9VTGnget","https://ap.wps.com/l/cbCaigEt9VTGnget","pdf",845256,18,"English","# Abstract\n## Purpose of Review\n## Recent Findings\n## Summary\n# Introduction\n# Toward a New Molecular Classification\n## Molecular heterogeneity and early classification attempts\n## Key molecular subtypes and biomarkers","[{\"question\":\"What is the main goal of the review on small cell lung cancer?\",\"answer\":\"To summarize recent advances in the molecular understanding of SCLC and potential new treatment strategies, including pathway, epigenetic, angiogenesis, and oncogenic-driver targeting.\"},{\"question\":\"How has immunotherapy changed outcomes in extensive-disease SCLC?\",\"answer\":\"Adding immunotherapy to chemotherapy has significantly improved clinical outcomes and overall survival, even though the prognosis remains dismal.\"},{\"question\":\"Why is molecular classification important for SCLC treatment development?\",\"answer\":\"Multiple genomic alterations enable stratification into molecular subtypes, which may help identify therapeutic targets and guide more effective targeted treatment strategies.\"}]","Novel Therapeutic Options for Small Cell Lung Cancer | PDF",1790261697,45]